MEK 抑制通过肿瘤细胞噬作用诱导的 CXCL10 表达增强化疗免疫治疗。
MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression.
机构信息
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
Cell Rep Med. 2022 Jan 18;3(1):100506. doi: 10.1016/j.xcrm.2021.100506.
Abstract
A recent study by Limagne et al. in demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.
摘要
利马涅等人最近的一项研究表明，在标准护理铂类/培美曲塞中加入 MEK 抑制剂可通过视神经萎缩蛋白和 TLR9 促进有丝分裂依赖性 CXCL10 表达。肿瘤细胞分泌的 CXCL10 可产生 T 细胞募集并增强免疫治疗效果。
相似文献
1
MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression.MEK 抑制通过肿瘤细胞噬作用诱导的 CXCL10 表达增强化疗免疫治疗。
Cell Rep Med. 2022 Jan 18;3(1):100506. doi: 10.1016/j.xcrm.2021.100506.
2
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.MEK 抑制通过诱导癌细胞中的 CXCL10 克服化疗免疫治疗耐药性。
Cancer Cell. 2022 Feb 14;40(2):136-152.e12. doi: 10.1016/j.ccell.2021.12.009. Epub 2022 Jan 19.
3
Mitophagy: a new actor in the efficacy of chemo-immunotherapy.自噬：化疗免疫治疗疗效的新因素。
Autophagy. 2022 Dec;18(12):3033-3034. doi: 10.1080/15548627.2022.2069439. Epub 2022 May 9.
4
MAPK signaling regulates the efficacy of chemoimmunotherapy.丝裂原活化蛋白激酶（MAPK）信号传导调节化学免疫疗法的疗效。
Mol Cell Oncol. 2022 Apr 27;9(1):2054652. doi: 10.1080/23723556.2022.2054652. eCollection 2022.
5
Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.催乳素可增强干扰素-γ诱导人角质形成细胞产生CXC配体9（CXCL9）、CXCL10和CXCL11。
Endocrinology. 2007 May;148(5):2317-25. doi: 10.1210/en.2006-1639. Epub 2007 Jan 25.
6
A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy.一种新型基于 CXCL10 的 GPI 锚定融合蛋白作为 NK 细胞为基础的肿瘤治疗佐剂。
PLoS One. 2013 Aug 30;8(8):e72749. doi: 10.1371/journal.pone.0072749. eCollection 2013.
7
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.免疫细胞和肿瘤细胞来源的 CXCL10 可作为转移性黑色素瘤免疫治疗反应的标志物。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-003521.
8
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.MEK 抑制通过增加肿瘤细胞杀伤和 T 细胞激活增强溶瘤病毒免疫疗法。
Sci Transl Med. 2018 Dec 12;10(471). doi: 10.1126/scitranslmed.aau0417.
9
CXCL10 contributes to p38-mediated apoptosis in primary T lymphocytes in vitro.CXCL10 有助于体外原代 T 淋巴细胞中 p38 介导的细胞凋亡。
Cytokine. 2012 Aug;59(2):433-41. doi: 10.1016/j.cyto.2012.05.002. Epub 2012 May 30.
10
Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4, CD8 T cells, and M1 macrophages.计划中的缺陷：miR-34a-5p 通过调节 CD4、CD8 T 细胞和 M1 巨噬细胞中的 CXCL10/CXCL11/CXCR3 轴来影响趋化因子信号。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001617.
引用本文的文献
1
Nanoscale covalent organic framework-mediated pyroelectrocatalytic activation of immunogenic cell death for potent immunotherapy.基于纳米尺度共价有机框架介导的免疫原性细胞死亡的热声电催化激活作用用于有效的免疫治疗。
Sci Adv. 2024 Nov 29;10(48):eadr5145. doi: 10.1126/sciadv.adr5145.
本文引用的文献
1
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.获得性抗丝裂原活化蛋白激酶（MAPK）靶向治疗耐药赋予黑色素瘤免疫逃逸的肿瘤微环境及对免疫治疗的交叉耐药性。
Nat Cancer. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15.
2
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.MEK 抑制通过诱导癌细胞中的 CXCL10 克服化疗免疫治疗耐药性。
Cancer Cell. 2022 Feb 14;40(2):136-152.e12. doi: 10.1016/j.ccell.2021.12.009. Epub 2022 Jan 19.
3
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.抗 PD-1/L1 先导治疗联合 MAPK 抑制剂可最大限度提高抗肿瘤免疫和疗效。
Cancer Cell. 2021 Oct 11;39(10):1375-1387.e6. doi: 10.1016/j.ccell.2021.07.023. Epub 2021 Aug 19.
4
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.Th17 细胞有助于 MEK 抑制剂联合抗 PD-L1 治疗 KRAS/p53 突变型肺癌的耐药。
Nat Commun. 2021 May 10;12(1):2606. doi: 10.1038/s41467-021-22875-w.
5
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.晚期非小细胞肺癌（NSCLC）和 KRAS 突变患者中应用比尼替尼、培美曲塞和顺铂治疗，随后行比尼替尼和培美曲塞维持治疗：SAKK 19/16 期临床试验。
Lung Cancer. 2021 Jun;156:91-99. doi: 10.1016/j.lungcan.2021.04.002. Epub 2021 Apr 25.
6
MEK inhibition reprograms CD8 T lymphocytes into memory stem cells with potent antitumor effects.MEK 抑制将 CD8 T 淋巴细胞重编程为具有强大抗肿瘤作用的记忆干细胞。
Nat Immunol. 2021 Jan;22(1):53-66. doi: 10.1038/s41590-020-00818-9. Epub 2020 Nov 23.
7
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.西罗莫司治疗接受标准培美曲塞和铂类化疗的晚期或转移性 KRAS 野生型或未知非鳞状非小细胞肺癌患者：一项随机、多中心、II 期研究。加拿大癌症临床试验组（CCTG）IND.219。
Lung Cancer. 2019 Jul;133:48-55. doi: 10.1016/j.lungcan.2019.04.027. Epub 2019 May 1.
8
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.RAF→MEK→ERK 抑制诱导的保护性自噬提示了一种针对 RAS 驱动型癌症的治疗策略。
Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4.
9
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
10
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.MAP 激酶抑制与 PD-L1 检查点阻断联合促进 T 细胞和抗肿瘤活性。
Immunity. 2016 Mar 15;44(3):609-621. doi: 10.1016/j.immuni.2016.01.024. Epub 2016 Mar 2.
Zotero 插件